-
1.发明申请2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders 失效可用于治疗高增殖性，血管生成和炎性疾病的2-氧代-1,3,5-全氢三氮杂衍生物公开(公告)号：US20050032798A1
公开(公告)日：2005-02-10
申请号：US10788405
申请日：2004-03-01
申请人： Stephen Boyer , Jacques Dumas , Barton Phillips , William Scott , Roger Smith , Jianqing Chen , Benjamin Jones , Gan Wang
发明人： Stephen Boyer , Jacques Dumas , Barton Phillips , William Scott , Roger Smith , Jianqing Chen , Benjamin Jones , Gan Wang
IPC分类号： A61K31/335 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/423 , A61K31/428 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/444 , A61K31/4709 , A61K31/498 , A61K31/53 , A61K31/538 , A61K31/5415 , A61P35/00 , C07D213/68 , C07D213/79 , C07D213/84 , C07D251/02 , C07D333/66 , C07D401/12 , C07D405/12 , C07D417/12
CPC分类号： C07D213/84 , C07D401/12 , C07D405/12 , C07D417/12
摘要： This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
摘要翻译： 本发明涉及新的二芳基脲，含有这些化合物的药物组合物以及这些化合物或组合物用于治疗高增殖和血管生成障碍，作为唯一试剂或与细胞毒性疗法组合的用途。
-
2.发明申请Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders 有权用于治疗癌症和其他疾病的新型双环脲衍生物公开(公告)号：US20050038031A1
公开(公告)日：2005-02-17
申请号：US10788426
申请日：2004-03-01
申请人： Jacques Dumas , Stephen Boyer , Sharad Verma , Lila Adnane , Yuanwei Chen , Wendy Lee , Barton Phillips , Roger Smith , William Scott , Jennifer Burke , Jianqing Chen , Zhi Chen , Jianmei Fan , Karl Miranda , Brian Raudenbush , Aniko Redman , Jianxing Shao , Ning Su , Gan Wang , Lin Yi , Qingming Zhu
发明人： Jacques Dumas , Stephen Boyer , Sharad Verma , Lila Adnane , Yuanwei Chen , Wendy Lee , Barton Phillips , Roger Smith , William Scott , Jennifer Burke , Jianqing Chen , Zhi Chen , Jianmei Fan , Karl Miranda , Brian Raudenbush , Aniko Redman , Jianxing Shao , Ning Su , Gan Wang , Lin Yi , Qingming Zhu
IPC分类号： A61K31/335 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/423 , A61K31/428 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/444 , A61K31/4709 , A61K31/498 , A61K31/53 , A61K31/538 , A61K31/5415 , A61P35/00 , C07D213/68 , C07D213/79 , C07D213/84 , C07D251/02 , C07D333/66 , C07D401/12 , C07D405/12 , C07D417/12
CPC分类号： C07D213/84 , C07D401/12 , C07D405/12 , C07D417/12
摘要： This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
摘要翻译： 本发明涉及新的二芳基脲，含有这些化合物的药物组合物以及这些化合物或组合物用于治疗高增殖和血管生成障碍，作为唯一试剂或与细胞毒性疗法组合的用途。
-
3.发明申请公开(公告)号：US20060019990A1
公开(公告)日：2006-01-26
申请号：US11158048
申请日：2005-06-22
申请人： Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
发明人： Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号： A61K31/4709 , A61K31/444 , C07D401/02
CPC分类号： C07D213/40
摘要： The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
摘要翻译： 本发明涉及一组喹啉基，异喹啉基和吡啶基脲，它们在治疗raf介导的疾病中的用途，以及含有用于这种治疗的这些尿素的药物组合物。
-
4.发明授权Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors 有权羟基，ω-羧基芳基取代的二苯基脲和其衍生物作为raf激酶抑制剂公开(公告)号：US07528255B2
公开(公告)日：2009-05-05
申请号：US10071248
申请日：2002-02-11
申请人： Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood
发明人： Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号： C07D211/72 , C07D213/62 , C07D213/78
CPC分类号： C07D295/192 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/5377 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/36 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D209/50 , C07D213/75 , C07D213/80 , C07D213/81 , C07D295/073 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D401/12 , C07F7/1804
摘要： The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula wherein, Y is NHR Hal is chlorine or bromine, R is H, CH3 or CH2OH, and X1 to X7 are each, independently, H, OH or —OC(O)C1-C4 alkyl, or a salt purified stereoisomer thereof, wherein at least one of X1 to X7 is OH or —OC(O)C1-C4 alkyl.
摘要翻译： 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途以及用于下列治疗的药物组合物：其中Y是NHR Hal是氯或溴，R是H，CH3或CH2OH，X1至 X 7各自独立地为H，OH或-OC（O）C 1 -C 4烷基或其盐纯化的立体异构体，其中X 1至X 7中的至少一个为OH或-OC（O）C 1 -C 4烷基。
-
5.发明申请公开(公告)号：US20080027061A1
公开(公告)日：2008-01-31
申请号：US11845597
申请日：2007-08-27
申请人： Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
发明人： Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
IPC分类号： A61K31/535 , A61K31/17 , A61P19/02 , A61K31/495
CPC分类号： A61K31/5377 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/473
摘要： This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译： 本发明涉及一组芳基脲在治疗p38介导的疾病中的用途，以及用于此类治疗的药物组合物。
-
6.发明申请INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS 失效使用ARYL和HETEROARYL取代的杂环类URAAS对RAF激酶的抑制作用公开(公告)号：US20080009527A1
公开(公告)日：2008-01-10
申请号：US11768533
申请日：2007-06-26
申请人： Jacques Dumas , Uday Khire , Timothy Lowinger , Bernard Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人： Jacques Dumas , Uday Khire , Timothy Lowinger , Bernard Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号： A61K31/4439 , A61K31/415 , A61P35/00 , C07D401/12 , C07D405/04 , C07D231/38 , A61K31/443
CPC分类号： C07D231/40 , C07D333/36 , C07D401/12 , C07D405/04
摘要： Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se,
摘要翻译： 用raf激酶介导的肿瘤治疗方法，用取代的脲化合物和这些化合物本身，
-
公开(公告)号：US20070244120A1
公开(公告)日：2007-10-18
申请号：US11768112
申请日：2007-06-25
申请人： Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
发明人： Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
IPC分类号： A61K31/5377 , A61K31/09 , A61K31/136 , A61K31/381 , A61K31/4164 , A61K31/4196 , A61K31/42 , A61K31/426 , C07D401/12 , C07D231/10 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497
CPC分类号： C07D231/40 , C07D207/34 , C07D259/00 , C07D261/14 , C07D271/113 , C07D285/135 , C07D333/36 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
摘要翻译： 治疗由raf激酶介导的肿瘤与取代的脲化合物及其化合物本身的方法。
-
8.发明申请公开(公告)号：US20070265315A1
公开(公告)日：2007-11-15
申请号：US11775457
申请日：2007-07-10
申请人： Jacques Dumas , William Scott , Bernd Riedl
发明人： Jacques Dumas , William Scott , Bernd Riedl
IPC分类号： A61K31/44 , A61P35/00 , C07D211/72
CPC分类号： C07D213/89 , C07D215/60 , C07D217/08
摘要： This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angogenesis disorders.
摘要翻译： 本发明涉及含有吡啶，喹啉或异喹啉官能团的脲化合物，其在氮杂原子处被氧化并且可用于治疗（i）raf介导的疾病，例如癌症，（ii）p38介导的疾病，例如 炎症和骨质疏松症，和（iii）VEGF介导的疾病，如血管发生障碍。
-
公开(公告)号：US07351834B1
公开(公告)日：2008-04-01
申请号：US09889227
申请日：2000-01-12
申请人： Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger A. Smith , Jill E. Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
发明人： Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger A. Smith , Jill E. Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
IPC分类号： C07D213/30 , A61K31/44
CPC分类号： C07D209/48 , C07C251/48 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/36 , C07C275/40 , C07C311/29 , C07C317/22 , C07D207/09 , C07D209/46 , C07D213/74 , C07D213/75 , C07D213/79 , C07D213/81 , C07D213/82 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D295/192 , C07D307/14 , C07D401/12
摘要： This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译： 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途，以及用于此类治疗的药物组合物。
-
公开(公告)号：US20050059703A1
公开(公告)日：2005-03-17
申请号：US10848567
申请日：2004-05-19
申请人： Scott Wilhelm , Jacques Dumas , Gaetan Ladouceur , Mark Lynch , William Scott
发明人： Scott Wilhelm , Jacques Dumas , Gaetan Ladouceur , Mark Lynch , William Scott
IPC分类号： A61K31/00 , A61K31/4412 , A61K31/4418 , A61K31/443 , A61K45/06 , A61L31/16
CPC分类号： A61K45/06 , A61K31/00 , A61K31/16 , A61K31/165 , A61K31/4412 , A61K31/4418 , A61K31/443 , A61K31/66 , A61L31/16 , A61L2300/204 , A61L2300/416 , G01N33/5041 , G01N33/5743 , G01N33/57438 , A61K2300/00
摘要： The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.
摘要翻译： 本发明提供了通过施用式I的二芳基脲来治疗和/或预防与包含血小板衍生生长因子受体（PDGFR）的信号转导途径相关和/或介导的人和其他哺乳动物的病症和疾病的方法。 本发明还提供了用于治疗，改善，预防或调节影响或损伤血管系统的血管造影手术或其他侵入性程序后的再狭窄的装置和方法，以及将供体组织移植到宿主中之后的移植物排斥，其中支架或其他 可植入装置包含有效量的式I的二芳基脲。
-
-
-
-
-
-
-
-
-
搜索结果
85 条记录 (耗时 0.047 秒)
